Please use this identifier to cite or link to this item:
https://wslhd.intersearch.com.au/wslhdjspui/handle/1/9029
Title: | Characterizing the acute antibody response of monkeypox and MVA-BN vaccine following an Australian outbreak |
Authors: | Asquith, Will;Hueston, Linda;Dwyer, Dominic E.;Kok, Jen;Ko, Danny;Fennell, Michael;Rockett, R.;Rai, Neela J.;Li, Ying;Sriramoju, Shirisha;Sutor, Allison;O'Sullivan, Matthew V. N. |
WSLHD Author: | Asquith, Will;Hueston, Linda;Dwyer, Dominic E.;Kok, Jen;Ko, Danny;Fennell, Michael;Rai, Neela J.;Li, Ying;Sriramoju, Shirisha;Sutor, Allison;O'Sullivan, Matthew V. N. |
Subjects: | Infectious Diseases |
Issue Date: | 2024 |
Citation: | Journal of Medical Virology 96(1):e29407, 2024 |
Abstract: | In response to the emergence of the monkeypox virus (MPXV) in Australia in May 2022, we developed and evaluated indirect immunofluorescence assays (IFA) for MPXV and Vaccinia virus (VACV) IgG and IgM antibodies using serum samples from patients with nucleic acid amplification test (NAAT)-confirmed mpox and uninfected unvaccinated controls. Additionally, 47 healthcare workers receiving two doses of the third-generation smallpox vaccine Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) undertook serial serum collection to describe the serological response to vaccination. MPXV antibodies were detected in 16/18 individuals with NAAT-confirmed mpox (sensitivity 0.89, specificity 1.00), and VACV antibodies were detected in 28/29 individuals who received two doses of MVA-BN vaccine (sensitivity 0.97, specificity 1.00). Detectable antibody in subjects historically vaccinated with early-generation vaccines against smallpox was found in 7/7 subjects, at a median of 48 years following vaccination. MPXV NAAT-positive patients with serum samples collected within the first 14 days after rash onset had detectable IgG and IgM in 9/12 and 5/12 of patients, respectively, with maintenance of IgG and disappearance of IgM titers after 60 days. While specificity was high when testing unvaccinated and uninfected subjects, significant cross-reactivity between MPXV and VACV antibodies was observed. |
URI: | https://wslhd.intersearch.com.au/wslhdjspui/handle/1/9029 |
DOI: | https://dx.doi.org/10.1002/jmv.29407 |
Journal: | Journal of Medical Virology |
Type: | Journal Article |
Study or Trial: | Controlled Study |
Department: | Pathology Infectious Diseases |
Facility: | Blacktown Westmead Auburn |
Affiliated Organisations: | Institute of Clinical Pathology and Medical Research, NSW Health Pathology, Westmead, NSW, Australia Sydney Infectious Disease Institute, The University of Sydney, Camperdown, NSW, Australia Centre for Infectious Diseases and Microbiology, Westmead Hospital, Westmead, NSW, Australia |
Keywords: | antibody response cross reaction drug therapy indirect fluorescent antibody technique monkeypox nucleic acid amplification techniques rash smallpox Vaccinia virus imunoglobulin G mmunoglobulin M immunoglobulin M antibody smallpox vaccine vaccine valaciclovir |
Appears in Collections: | Blacktown Mount Druitt Hospital |
Files in This Item:
There are no files associated with this item.
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.